Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer
Gregor Tevz, Sean McGrath, Ryan Demeter, Vincent Magrini, Varinder Jeet, Anja Rockstroh, Stephen McPherson, John Lai, Nenad Bartonicek, Jiyuan An, Jyotsna Batra, Marcel E Dinger, Melanie L Lehman, Elizabeth D Williams, Colleen C Nelson
MOLECULAR AND CELLULAR ENDOCRINOLOGY | ELSEVIER IRELAND LTD | Published : 2016
Simultaneous expression of highly homologous RLN1 and RLN2 genes in prostate impairs their accurate delineation. We used PacBio SMRT sequencing and RNA-Seq in LNCaP cells in order to dissect the expression of RLN1 and RLN2 variants. We identified a novel fusion transcript comprising the RLN1 and RLN2 genes and found evidence of its expression in the normal and prostate cancer tissues. The RLN1-RLN2 fusion putatively encodes RLN2 isoform with the deleted secretory signal peptide. The identification of the fusion transcript provided information to determine unique RLN1-RLN2 fusion and RLN1 regions. The RLN1-RLN2 fusion was co-expressed with RLN1 in LNCaP cells, but the two gene products were i..View full abstract
This work was supported by the Australian Government Department of Health; the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award.